CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.

Presentation Details

Date: Tuesday, April 8, 2025

Time: 3:00 PM EDT

Webcast Link:

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’  page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .

Investor Contact



Media Contact

Anna Gifford, Chief of Staff



617-500-8099



EN
02/04/2025

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces First Patient Dosed in an Investigator ...

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract ca...

April 21, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targete...

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: Virtual/Replay availability: The corporate presentation will be a...

April 2, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized P...

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent ce...

April 1, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Da...

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Pha...

March 31, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports 2024 Financial Results and Provides Corpo...

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025.Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.Continued to advance CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards expected year-end 2025 IND filing, with...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch